SB 208

Drug Profile

SB 208

Alternative Names: NVN 1000; SB208

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Novan Inc
  • Class Antifungals; Macromolecular substances; Nitrogen oxides
  • Mechanism of Action Cell death stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tinea pedis
  • Preclinical Onychomycosis

Most Recent Events

  • 12 Apr 2017 Efficacy data from a phase II trial in Tinea pedis released by Novan
  • 12 Apr 2017 Novan plans a phase II trial for Onchomycosis
  • 21 Jul 2016 Phase-II clinical trials in Tinea pedis in Dominican Republic (Topical) (NCT02860052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top